Figure 2

DAB/IL2 transiently depletes CD4⁺/CD25^HI/Foxp3⁺ T cells. Whole blood was collected from patient P9 during cycle one of DAB/IL2 administration just prior to the first (day 0) and last dose (day 3) and then 7 and 21 days after initiation of DAB/IL2 therapy. The peripheral blood mononuclear cells were isolated from the whole blood by Ficoll gradient centrifugation and stained with fluorescent conjugates of monoclonal antibodies specific for CD4, CD25 and Foxp3. In order to quantify the percentage of CD4⁺/CD25^HI/Foxp3⁺ T cells within the total lymphocyte forward/side scatter gate, the CD4⁺/CD25^HI cells (right panels) were gated and analyzed for Foxp3 expression (left panels).